tbuckley/cabot-search huggingface dataset:
"THE SOURCE OF TUBERCULOSIS IN CHILDHOOD"
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1215: Improved T cell activation bioassays for development of bispecific antibodies and engineered T cell immunotherapies
Authors: Pete Stecha, Denise Garvin, Jim Hartnett, Brad Swanson, Frank Fan, Mei Cong, Zhi-jie Jey Cheng
Journal: Cancer Research (2019)

Abstract T Cell-mediated immunity is driven by activation of T cell which results in long-term, antigen-specific, effector and memory responses. In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of diseases such as cancer and autoimmunity. Current methods used to measure TCR-mediated T cell proliferation and cytokine production rely on primary PBMCs as a source of T cells, which must be stimulated via co-culture with APCs or anti-TCR/CD3 antibodies. These assays are laborious and highly variable due to their reliance on donor primary cells, complex assay protocols and unqualified assay reagents. As a result, these assays are difficult to establish in quality-controlled drug development settings. To overcome this barrier, we developed two reporter-based bioluminescent T cell activation bioassays that can be used for the development of bispecific antibodies and engineered T cell immunotherapies. The assays consist of Jurkat T cells genetically engineered to express luciferase downstream of either NFAT or IL-2 response elements. The T cell activation bioassays reflect the mechanisms of action of biologics designed to induce TCR and/or CD28-mediated T cell activation, as demonstrated using anti-CD3 and/or anti-CD28 antibodies as well as blinatumomab, a bispecific antibody that simultaneously binds CD3 expressed on T cells and CD19 expressed on malignant B cells. The bioassays are pre-qualified according to ICH guidelines and show assay specificity, precision, accuracy and linearity required for routine use in potency and stability studies. Finally, our data illustrate the use of reporter-based T cell activation bioassays for characterizing and measuring the activity of engineered chimeric antigen receptor T cells. Citation Format: Pete Stecha, Denise Garvin, Jim Hartnett, Brad Swanson, Frank Fan, Mei Cong, Zhi-jie Jey Cheng. Improved T cell activation bioassays for development of bispecific antibodies and engineered T cell immunotherapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1215.
Today's Challenge
Authors: Harry Marchmont-Robinson
Journal: JAMA (1968)

American medicine's greatest challenge today is the t delivery of competent, economical health care to the individual. In the past, medicine has concerned itself, as it should, with standards of education, research, ethics, and the advancement of the science. These policies have been effective in enabling American medicine to reach an historic pinnacle of competence and capability. This was primarily accomplished by an internal surveillance, which had as its goal the pursuit of excellence. Now, however, the profession is being subjected to an external surveillance which looks to the continuation of technical excellence, but which also wants the benefits available to each and every individual, regardless of race, color, creed, or financial position. Medicine has concerned itself primarily with the improvement of the product. Now, the public, for whom the product was designed, wants it distributed widely and economically. This is a new emphasis in American medicine. It has always
Claim that medical x-rays caused most US breast cancers found incredible
Authors: A. A. Skolnick
Journal: JAMA (1995)

A RESPECTED authority on the biological effects of ionizing radiation has just published a book claiming that the vast majority of breast cancers in the United States were caused by the high doses of medical x-rays that women often received in the decades before the carcinogenic effects of radiation were recognized. The book, which is based on one man's study of the medical literature going back to 1910, concludes that medical x-rays are responsible for at least 62%, and probably more than 75%, of the approximately 182 000 cases of breast cancer diagnosed each year in the United States. However, the study, which has not been peer reviewed, is not persuading leading cancer and radiation experts, who say there are major problems with some of the assumptions and conclusions of its author, John W. Gofman, MD, PhD, professor emeritus of molecular and cell biology at the University of California, Berkeley.
Reply
Authors: S. Izaki, K. Kitamura
Journal: British Journal of Dermatology (1997)

Journal Article Reply Get access S. Izaki, S. Izaki Dermatology, Saitama Medical Center, Saitama Medical School, 1981 Kamoda‐Tsujido, Kawagoe, Saitama 350, Japan Search for other works by this author on: Oxford Academic Google Scholar K. Kitamura K. Kitamura Dermatology, Saitama Medical Center, Saitama Medical School, 1981 Kamoda‐Tsujido, Kawagoe, Saitama 350, Japan Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 136, Issue 3, 1 March 1997, Page 467, https://doi.org/10.1111/j.1365-2133.1997.tb14969.x Published: 01 March 1997
Abstract 559: Diacylglycerol Kinase-ζ Rescues Gαq-induced Heart Failure
Authors: Takeshi Niizeki, Yasuchika Takeishi, Yo Koyama, Tatsuro Kitahara, Satoshi Suzuki, Ulrike Mende, Isao Kubota
Journal: Circulation (2007)

Background: It has been reported that the expression of a constitutively active mutant of the G protein αq subunit in the hearts of transgenic mice (Gαq-TG) induces cardiac hypertrophy and lethal heart failure. Thus, the Gαq protein-coupled receptor (GPCR) signaling pathway, which includes diacylglycerol (DAG) and protein kinase C (PKC), plays a critical role in the development of cardiac hypertrophy and heart failure. DAG kinase (DGK) catalyzes DAG and controls cellular DAG levels, and thus may act as a negative regulator of GPCR signaling. In this study, we tested the hypothesis that DGKζ rescues Gαq-TG mice from developing heart failure. Methods and Results: We generated double transgenic mice (Gαq/DGKζ-TG) with cardiac-specific overexpression of both DGKζ and constitutive active Gαq by crossing Gαq-TG mice with transgenic mice with cardiac-specific overexpression of DGKζ (DGKζ-TG), and the pathophysiological consequences were analyzed. DGKζ inhibited cardiac hypertrophy and progression to heart failure in Gαq-TG mice (Table ). DGKζ prevented dilatation of left ventricular dimension and reduction of left ventricular fractional shortening in Gαq-TG mice. Markedly increased left ventricular end-diastolic pressure in Gαq-TG mice was normalized in Gαq/DGKζ-TG mice. Increases in heart weight/body weight ratio and cardiomyocyte cross sectional area were attenuated in Gαq/DGKζ-TG mice. Translocation of PKC α and ε isoforms, activation of JNK and p38 MAPK induced by Gαq were attenuated by DGKζ. DGKζ reduced fibrotic changes and concomitant upregulation of fibrosis-related genes such as collagen type I and type III induced by Gαq. DGKζ improved the survival rate of Gαq-TG mice. Conclusions: These results demonstrate the first evidence that DGKζ prevents cardiac dysfunction and heart failure by activated Gαq without detectable adverse effects in in vivo hearts and suggest that DGKζ represents a novel therapeutic target for cardiac hypertrophy and heart failure. Summary of the results
Pharmacogenetics. Glucose-6-phosphate dehydrogenase deficiency
Authors: S. Wessler
Journal: JAMA (1968)

Dr. Richard Miller, Senior Assistant Resident in Medicine, Jewish Hospital of St. Louis, and Assistant in Medicine, Washington University School of Medicine: A 32-year-old, Negro woman was admitted to the Jewish Hospital for the first time on Aug 4, 1967, because of a ten months' history of diffuse abdominal pain, which had begun after the delivery of her eighth child. The pain was gnawing, occasionally sharp, and resistant to all medication. The patient also had had anorexia, hematemesis, and a 40.9-kg (90-lb) weight loss. The hematocrit reading was 39% on her clinic visit of July 27, when treatment with prochlorperazine (Compazine), chloral hydrate, and an analgesic (Darvon Compound) was started. She had been hospitalized in 1960 and 1967 for psychiatric illnesses. Physical examination on admission was completely unremarkable. Hematocrit value was 33%, white blood cell count was 7,200/cu mm, and differential count was normal, platelets were adequate, reticulocyte count was
Abstract P009: The Association of Liver Enzymes with Subclinical Myocardial Damage
Authors: Mariana Lazo, Jonathan Rubin, Jeanne M Clark, Frederick L Brancati, Andrea Christman, Chiadi Ndumele, Ron C Hoogeveen, Christie M Ballantyne, Elizabeth Selvin
Journal: Circulation (2012)

Background: Nonalcoholic fatty liver disease (NAFLD) is present in up to 30% of the US population and is strongly associated with obesity and diabetes. While a number of studies support an association between NAFLD and cardiovascular disease, limited evidence exists for the association with subclinical myocardial injury. Objective: To test the hypothesis that elevated liver enzymes (Alanine aminotrasferase [ALT], Aspartate aminotranferase [AST] and Gamma-glutamyl transpeptidase [GGT]) in the absence of significant alcohol consumption are independently associated with subclinical myocardial injury, defined by elevated cardiac troponin-T measured using a highly-sensitive assay (hs-cTnT). Methods: We conducted a cross-sectional analysis of 9351 participants from the Atherosclerosis Risk in the Communities (ARIC) Study with information on ALT, AST and GGT , hs-cTnT, and no evidence of coronary heart disease or elevated alcohol consumption (&gt;14 and &gt;21 drinks/week for women and men, respectively). We used logistic regression models to examine the association between liver enzymes and elevated hs-TnT (hs-TnT &gt;0.014 μ g/L ) defined in a healthy reference population. Our secondary outcome was detectable hs-TnT (&gt;0.003 μ g/L ). Results: In this community-based population (mean age 63 years, 60% women, 78% white), 7.2% and 66.1% had elevated and detectable hs-TnT, respectively. Medians [range] of ALT, AST and GGT were 13 [1-381], 18 [5-358] and 21 [2-1277], respectively. Higher levels of ALT, AST and GGT, even within the normal range, were independently associated with elevated hs-TnT (Figure). ALT and AST were also independently associated with detectable hs-TnT. After excluding participants with heart failure, the results remained consistent. Conclusions: In this sample, elevated livers enzymes were independently associated with subclinical myocardial damage suggesting that NAFLD may contribute to myocardial injury beyond its effects on development of clinical atherosclerotic coronary disease.
Occluded arteries should be in an ACC/AHA class by themselves. An analysis of data from the society for cardiac angiography and Interventions' (SCA&amp;I) registry
Authors: R.J. Krone, W. Laskey, J.J.A. Cosentino, S. Kimmel, J. Babb, S.A. Johnson, E. Schechter, B. Weiner
Journal: Journal of the American College of Cardiology (1998)
GONORRHEA AND DRUNKENNESS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
How the Opium Habit Is Acquired
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ROCKY MOUNTAIN SPOTTED FEVER
Authors: R. R. Parker
Journal: JAMA (1933)

<h3>To the Editor:</h3> —The following quotation is from an editorial on Rocky Mountain spotted fever, which appeared inThe Journal, August 19. The following comments are made as a reply to the statements made in the editorial: A much neglected phase of this problem has been revived by the work of Zinsser and Ruiz Castaneda on Mexican typhus, a disease that seems quite closely related to Rocky Mountain spotted fever. These workers produced a highly protective serum for the guinea-pig by immunizing a horse to a phenolized suspension of Rickettsia obtained from infected rats previously irradiated with x-rays. The early immune serum studies of Ricketts and Gomez and of Heinemann and Moore and the later ones of Noguchi are then referred to, and the editorial goes on as follows: Despite these encouraging experimental results, there has been no further report of an attempt to increase the potency of immune serum
A Century with Norfolk Naval Hospital, 1830-1930. A Story of the Oldest Naval Hospital, the Medical Department of the Navy and the Progress of Medicine Through the Past One Hundred Years.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
1041. Ex Vivo Soluble Fas Ligand Treatment of Donor Cells to Selectively Reduce Murine Acute Graft Versus Host Disease
Authors: Robert W. Georgantas, Osnat Bohana-Kashtan, Curt I. Civin
Journal: Molecular Therapy (2006)

Allogeneic bone marrow transplantation (BMT) and donor lymphocyte infusion (DLI) provide valuable treatments for a range of diseases. However, the therapeutic utility of BMT and DLI is reduced by the high incidence of graft versus host disease (GvHD) mediated by activated donor T lymphocytes directed against recipient alloantigens. Using mouse models, we developed and evaluated a strategy to selectively enhance activation-induced cell death (AICD) of anti-recipient T cells within transplant donor cell populations, with the goal of reducing GvHD. Responder T lymphocytes were incubated ex vivo with irradiated allogenic stimulator cells in a mixed lymphocyte reaction (MLR) in the presence of soluble Fas ligand (sFasL). This ex vivo sFasL treatment reduced proliferation to the allogeneic stimulator cells in vitro andabrogated acute GvHD capacity in vivo. In contrast, the secondary immune responsiveness of the ex vivo sFasL-treated responder T cells to an unrelated model antigen was preserved. Furthermore, upon adoptive transfer in a DLI model, ex vivo sFasL-treated T cells were able to reject a model tumor. Finally, ex vivo sFasL treatment of bone marrow cells did not reduce their hematopoietic engraftment capacity. Thus, ex vivo treatment with sFasL appears to have potential for translation to clinical cell processing of BMT allografts and DLI infusions.
Venetoclax Data Prompt Rethink of CLL Therapy
Journal: Cancer Discovery (2018)

Abstract The BCL2 inhibitor venetoclax is approved in the United States for only a subset of patients with refractory chronic lymphocytic leukemia. However, in light of data presented at the American Society of Hematology 2017 Annual Meeting, clinicians are thinking ahead to administering the drug more broadly—in combinations and as a first-line therapy—for other patients with the disease.
EDDYISM VS. AN EDUCATED PUBLIC.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Insights into how to conduct a clinical trial in the UK
Authors: Khalid Abozguia, Thanh Trung Phan, Ganesh Nallur Shivu, Abdul Maher, Ibrar Ahmed, Michael P Frenneaux
Journal: Journal of the Royal Society of Medicine (2007)

Summary New researchers may find starting and conducting clinical studies in the UK complicated and time-consuming. In this article, we describe our collective experiences and provide some pointers on how to navigate through the various committees and regulatory bodies. The article is intended to aid junior researchers in understanding the study process and to provide them with some insight on how to get through this complex system successfully.
THE UNITED STATES PUBLIC HEALTH AND MARINE-HOSPITAL SERVICE.PART II—THE SERVICES AS IT IS TO-DAY
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal